Patients With Necrotizing Skin and Soft Tissue Infections Managed Within the Great Paris Area SURFAST Care Pathway: a Prospective, Multicenter Cohort Study.
Overview
- Phase
- Not Applicable
- Status
- Not yet recruiting
- Enrollment
- 1,000
- Locations
- 1
- Primary Endpoint
- mortality
Overview
Brief Summary
Necrotising soft-tissue infections (NSTIs) are rare and life-threatening skin and soft tissue infections requiring urgent combined medical and surgical management in specialist centres. At Assistance Publique-Hôpitaux de Paris, a multidisciplinary reference network called the SURFAST consortium has been established. This network includes experts in the management of NSTIs, such as intensivists, dermatologists, infectious disease physicians, paediatricians, surgeons, and microbiologists. The consortium manages all NSTI cases referred from the greater Paris area, a large region of France with a population exceeding 12 million.
The SURFAST network comprises care pathways enabling the management of adult and paediatric patients with abdomino-perineal, limb, and cervico-facial NSTIs. All patients managed within this care pathway are included in a prospective, multicentre cohort study. This study examines factors associated with mortality at day 90, long-term sequelae, quality of life, and indicators of the quality of care.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 0 Years to — (Child, Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- No
Inclusion Criteria
- •All patients (adults and children, irrespective of age) managed for suspected or surgically confirmed necrotizing soft-tissue infections (NSTI) • Consent to participate in the study
Exclusion Criteria
- •Patient or legal representative's refusal to participate in the study
Arms & Interventions
- Adult / limb and abdomino-perineal
- Adult / cervico-facial
- Pediatric
Outcomes
Primary Outcomes
mortality
Time Frame: 90 days
If the patient is still hospitalized, an on-site visit will be conducted; otherwise, the patient or their relative will be contacted by telephone by an investigator or a study coordinator
Secondary Outcomes
- functional outcome and quality of life(day 90 post-admission)
- amputation rate(day 90)
- annual case volume per centre(123 months)
- hospital mortality(at hospital discharge and within 60 days of hospital admission)
- time from hospital admission to first surgical debridement(within the first 72 hours of hospital admission)
- bacteriological documentation(At the time of blood culture collection or operative tissue sampling)